Search

Author/Creator Lorence, R.M.

1. Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib. (February 2017)

Authors:
Hochmair, M.; Cappuzzo, F.; Tsai, C.M.; Schuler, M.; Lam, K.C.; Stehle, G.; Cseh, A.; Lorence, R.M.; Linden, S.; Carrière, P.; Soo, R.
Journal:
European journal of cancer
Issue:
Volume 72(2017)Supplement 1
Page Start:
S183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search